STOCK TITAN

[Form 4] Thermo Fisher Scientific, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Thermo Fisher (TMO) Form 4 — insider dispositions by Sr. VP & CFO Stephen Williamson. The filing reports four open-market sales on 08/28/2025 totaling 783.273 shares at $489.74 per share. After these transactions, Williamson directly held 32,320.193 shares and is noted as indirectly beneficially owning 12,674 shares through a SLAT, with a disclaimer that he disclaims beneficial ownership except for any pecuniary interest. The form is signed by an attorney-in-fact on 09/02/2025.

Thermo Fisher (TMO) Modulo 4 — cessioni interne da parte del Senior VP e CFO Stephen Williamson. La comunicazione indica quattro vendite sul mercato aperto effettuate il 28/08/2025 per un totale di 783.273 azioni al prezzo di $489,74 per azione. Dopo queste operazioni, Williamson deteneva direttamente 32.320,193 azioni e risulta titolare indiretto di 12.674 azioni tramite una SLAT, con la precisazione che rinuncia alla titolarità beneficiaria salvo eventuali interessi pecuniari. Il modulo è firmato da un procuratore il 02/09/2025.

Thermo Fisher (TMO) Formulario 4 — disposiciones de un insider por el Sr. VP y CFO Stephen Williamson. El informe registra cuatro ventas en mercado abierto el 28/08/2025 por un total de 783.273 acciones a $489.74 por acción. Tras estas transacciones, Williamson poseía directamente 32.320,193 acciones y se le atribuye una tenencia indirecta de 12.674 acciones a través de una SLAT, con una renuncia a la titularidad beneficiaria salvo por cualquier interés pecuniario. El formulario está firmado por un apoderado el 02/09/2025.

Thermo Fisher (TMO) Form 4 — 수석 부사장이자 CFO인 Stephen Williamson의 내부자 처분. 신고서에는 2025-08-28에 총 783,273주를 주당 $489.74에 장외매도(오픈마켓 판매)한 네 건이 보고되어 있습니다. 이 거래들 이후 Williamson은 직접적으로 32,320.193주를 보유하고 있으며, SLAT를 통해 간접적으로 12,674주를 보유한 것으로 기재되어 있고, 금전적 이익을 제외한 수익적 소유권은 부인한다고 명시되어 있습니다. 해당 양식은 2025-09-02에 대리인이 서명했습니다.

Thermo Fisher (TMO) Formulaire 4 — cessions d'initié par le Sr. VP et CFO Stephen Williamson. Le dépôt fait état de quatre ventes en marché ouvert le 28/08/2025 totalisant 783.273 actions au prix de 489,74 $ par action. Après ces opérations, Williamson détenait directement 32.320,193 actions et est indiqué comme détenant indirectement 12.674 actions via une SLAT, avec une déclaration de renonciation à la propriété bénéficiaire sauf pour tout intérêt pécuniaire. Le formulaire est signé par un mandataire le 02/09/2025.

Thermo Fisher (TMO) Formular 4 — Insider-Veräußerungen durch Sr. VP & CFO Stephen Williamson. Die Einreichung meldet vier Verkäufe am offenen Markt am 28.08.2025 mit insgesamt 783.273 Aktien zu je $489,74. Nach diesen Transaktionen hielt Williamson unmittelbar 32.320,193 Aktien und wird ferner als indirekt wirtschaftlich Berechtigter von 12.674 Aktien durch eine SLAT genannt, wobei er die wirtschaftliche Eigentümerschaft mit Ausnahme etwaiger pecuniärer Interessen bestreitet. Das Formular wurde am 02.09.2025 von einem Bevollmächtigten unterzeichnet.

Positive
  • None.
Negative
  • Insider dispositions: Four sales totaling 783.273 shares on 08/28/2025 at $489.74 per share.
  • Reduction in direct holdings: Direct holdings reported decreased to 32,320.193 shares after the transactions.

Insights

TL;DR: CFO sold 783.273 shares at $489.74, reducing direct holdings modestly; transaction size appears routine for an executive.

The filing documents four separate dispositions on a single date totaling 783.273 shares at $489.74 each. Proceeds can be computed from these explicit amounts; the transactions reduced the reporting person’s direct holdings from 32,888.792 to 32,320.193 shares as shown. No option exercises, grants, or derivative transactions are reported. This is a clear disclosure of insider selling without additional context about purpose or a 10b5-1 plan on the face of the form.

TL;DR: Multiple same-day dispositions by the CFO warrant governance attention but are disclosed per Section 16 requirements.

The report meets Section 16 disclosure standards by listing each disposition and the post-transaction beneficial ownership, and it includes the required signature by an attorney-in-fact. The filing also includes an explicit disclaimer of indirect beneficial ownership and identifies the SLAT holding 12,674 shares. Absent additional information (e.g., a stated 10b5-1 plan), governance teams may note timing but cannot infer intent solely from this disclosure.

Thermo Fisher (TMO) Modulo 4 — cessioni interne da parte del Senior VP e CFO Stephen Williamson. La comunicazione indica quattro vendite sul mercato aperto effettuate il 28/08/2025 per un totale di 783.273 azioni al prezzo di $489,74 per azione. Dopo queste operazioni, Williamson deteneva direttamente 32.320,193 azioni e risulta titolare indiretto di 12.674 azioni tramite una SLAT, con la precisazione che rinuncia alla titolarità beneficiaria salvo eventuali interessi pecuniari. Il modulo è firmato da un procuratore il 02/09/2025.

Thermo Fisher (TMO) Formulario 4 — disposiciones de un insider por el Sr. VP y CFO Stephen Williamson. El informe registra cuatro ventas en mercado abierto el 28/08/2025 por un total de 783.273 acciones a $489.74 por acción. Tras estas transacciones, Williamson poseía directamente 32.320,193 acciones y se le atribuye una tenencia indirecta de 12.674 acciones a través de una SLAT, con una renuncia a la titularidad beneficiaria salvo por cualquier interés pecuniario. El formulario está firmado por un apoderado el 02/09/2025.

Thermo Fisher (TMO) Form 4 — 수석 부사장이자 CFO인 Stephen Williamson의 내부자 처분. 신고서에는 2025-08-28에 총 783,273주를 주당 $489.74에 장외매도(오픈마켓 판매)한 네 건이 보고되어 있습니다. 이 거래들 이후 Williamson은 직접적으로 32,320.193주를 보유하고 있으며, SLAT를 통해 간접적으로 12,674주를 보유한 것으로 기재되어 있고, 금전적 이익을 제외한 수익적 소유권은 부인한다고 명시되어 있습니다. 해당 양식은 2025-09-02에 대리인이 서명했습니다.

Thermo Fisher (TMO) Formulaire 4 — cessions d'initié par le Sr. VP et CFO Stephen Williamson. Le dépôt fait état de quatre ventes en marché ouvert le 28/08/2025 totalisant 783.273 actions au prix de 489,74 $ par action. Après ces opérations, Williamson détenait directement 32.320,193 actions et est indiqué comme détenant indirectement 12.674 actions via une SLAT, avec une déclaration de renonciation à la propriété bénéficiaire sauf pour tout intérêt pécuniaire. Le formulaire est signé par un mandataire le 02/09/2025.

Thermo Fisher (TMO) Formular 4 — Insider-Veräußerungen durch Sr. VP & CFO Stephen Williamson. Die Einreichung meldet vier Verkäufe am offenen Markt am 28.08.2025 mit insgesamt 783.273 Aktien zu je $489,74. Nach diesen Transaktionen hielt Williamson unmittelbar 32.320,193 Aktien und wird ferner als indirekt wirtschaftlich Berechtigter von 12.674 Aktien durch eine SLAT genannt, wobei er die wirtschaftliche Eigentümerschaft mit Ausnahme etwaiger pecuniärer Interessen bestreitet. Das Formular wurde am 02.09.2025 von einem Bevollmächtigten unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Williamson Stephen

(Last) (First) (Middle)
168 THIRD AVENUE

(Street)
WALTHAM MA 02451

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Sr. VP and CFO
3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/28/2025 F 214.674 D $489.74 32,888.792 D
Common Stock 08/28/2025 F 219.51 D $489.74 32,669.282 D
Common Stock 08/28/2025 F 237.883 D $489.74 32,431.399 D
Common Stock 08/28/2025 F 111.206 D $489.74 32,320.193 D
Common Stock 12,674 I By SLAT(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
/s/ Melodie T. Morin, Attorney-in-Fact for Stephen Williamson 09/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for Thermo Fisher (TMO)?

The Form 4 reports four dispositions by Sr. VP & CFO Stephen Williamson on 08/28/2025 totaling 783.273 shares at $489.74 per share.

How many shares does Stephen Williamson own after these transactions?

The filing shows 32,320.193 shares directly owned following the reported sales and 12,674 shares indirectly owned via a SLAT.

Was a 10b5-1 trading plan disclosed on the Form 4?

The form does not indicate that these transactions were executed pursuant to a 10b5-1 plan; no plan box or instruction is checked in the provided content.

Who signed the Form 4?

The Form 4 is signed by Melodie T. Morin, Attorney-in-Fact for Stephen Williamson on 09/02/2025.
Thermo Fishr Sci

NYSE:TMO

TMO Rankings

TMO Latest News

TMO Latest SEC Filings

TMO Stock Data

186.06B
376.94M
0.16%
91.85%
0.98%
Diagnostics & Research
Measuring & Controlling Devices, Nec
Link
United States
WALTHAM